# Endothelial Derived Hyperpolarization Factor and Vascular Control

> **NCT05176379** · PHASE4 · RECRUITING · sponsor: **University of Oklahoma** · enrollment: 30 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Fluconazole 150 mg

## Key facts

- **NCT ID:** NCT05176379
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-19
- **Primary completion:** 2024-12
- **Final completion:** 2025-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05176379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05176379, "Endothelial Derived Hyperpolarization Factor and Vascular Control". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05176379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*